Mersana Therapeutics (FRA:0M4) FCF Margin % : -302.28% (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Mersana Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Mersana Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was €-29.66 Mil. Mersana Therapeutics's Revenue for the three months ended in Dec. 2023 was €9.81 Mil. Therefore, Mersana Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -302.28%.

As of today, Mersana Therapeutics's current FCF Yield % is -48.09%.

The historical rank and industry rank for Mersana Therapeutics's FCF Margin % or its related term are showing as below:

FRA:0M4' s FCF Margin % Range Over the Past 10 Years
Min: -327060.47 Med: -249.77 Max: 121.19
Current: -464.66

During the past 9 years, the highest FCF Margin % of Mersana Therapeutics was 121.19%. The lowest was -327060.47%. And the median was -249.77%.

FRA:0M4's FCF Margin % is ranked worse than
66.09% of 1032 companies
in the Biotechnology industry
Industry Median: -148.935 vs FRA:0M4: -464.66

Mersana Therapeutics FCF Margin % Historical Data

The historical data trend for Mersana Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mersana Therapeutics FCF Margin % Chart

Mersana Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-162.26

-9,073.27

-327,531.58

-193.98

-464.12

Mersana Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-354.14	-383.45	-584.11	-604.74	-302.28

Competitive Comparison of Mersana Therapeutics's FCF Margin %

For the Biotechnology subindustry, Mersana Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mersana Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mersana Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Mersana Therapeutics's FCF Margin % falls into.

Mersana Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Mersana Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-156.853	/	33.796
	=	-464.12 %

Mersana Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-29.663	/	9.813
	=	-302.28 %

Mersana Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Mersana Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mersana Therapeutics (FRA:0M4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mersana Therapeutics Inc (FRA:0M4) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

MRSN:USA

Address

840 Memorial Drive, Cambridge, MA, USA, 02139

Website

https://www.mersana.com

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Mersana Therapeutics (FRA:0M4) Headlines

No Headlines